Michelle M. Boisen, MD, discusses the scoring system for optimal debulking in ovarian cancer.
Michelle M. Boisen, MD
Advertisement
Articles by Michelle M. Boisen, MD
Michelle M. Boisen, MD, discusses criteria for selecting patients with ovarian cancer for upfront surgery versus neoadjuvant chemotherapy.
Michelle M. Boisen, MD, discusses the selection of neoadjuvant chemotherapy versus upfront surgery for women with newly diagnosed ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Boisen on Neoadjuvant Chemotherapy Versus Upfront Surgery in Ovarian CancerPublished: January 29th 2020 | Updated:
Dr. Boisen on Selecting Patients for Surgery Versus Neoadjuvant Chemotherapy in Ovarian CancerPublished: April 7th 2020 | Updated:
Dr. Boisen on Scoring System for Optimal Debulking in Ovarian CancerPublished: April 8th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5